Ignite Creation Date:
2025-12-26 @ 11:14 AM
Ignite Modification Date:
2025-12-26 @ 11:14 AM
Study NCT ID:
NCT05878028
Status:
RECRUITING
Last Update Posted:
2024-05-23
First Post:
2023-05-06
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC
Sponsor:
Quanli Gao
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-09-16
Start Date Type:
ACTUAL
Primary Completion Date:
2025-09-15
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-09-15
Completion Date Type:
ESTIMATED
First Submit Date:
2023-05-06
First Submit QC Date:
None
Study First Post Date:
2023-05-26
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-05-21
Last Update Post Date:
2024-05-23
Last Update Post Date Type:
ACTUAL